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Abstract
Background: Despite the large body of literature demonstrating the effectiveness of cognitive behavioral treatments for
agoraphobia, many patients remain untreated because of various barriers to treatment. Web-based and mobile-based interventions
targeting agoraphobia may provide a solution to this problem, but there is a lack of research investigating the efficacy of such
interventions.
Objective: The objective of our study was to evaluate for the first time the effectiveness of a self-guided mobile-based intervention
primarily targeting agoraphobic symptoms, with respect to a generic mobile app targeting anxiety.
Methods: A Web-based randomized controlled trial (RCT) compared a novel mobile app designed to target agoraphobia (called
Agoraphobia Free) with a mobile app designed to help with symptoms of anxiety in general (called Stress Free). Both interventions
were based on established cognitive behavioral principles. We recruited participants (N=170) who self-identified as having
agoraphobia and assessed them online at baseline, midpoint, and end point (posttreatment) over a period of 12 weeks. The primary
outcome was symptom severity measured by the Panic and Agoraphobia Scale.
Results: Both groups had statistically significant improvements in symptom severity over time (difference –5.97, 95% CI –8.49
to –3.44, P<.001 for Agoraphobia Free and –6.35, 95% CI –8.82 to –3.87, P<.001 for Stress Free), but there were no significant
between-group differences on the primary outcome (difference 0.38, 95% CI –1.96 to 3.20, P=.64).
Conclusions: This is, to our knowledge, the first RCT to provide evidence that people who identify as having agoraphobia may
equally benefit from a diagnosis-specific and a transdiagnostic mobile-based intervention. We also discuss clinical and research
implications for the development and dissemination of mobile mental health apps.
Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN): 98453199; http://www.isrctn.com
/ISRCTN98453199 (Archived by WebCite at http://www.webcitation.org/6uR5vsdZw)
(J Med Internet Res 2017;19(11):e398)   doi:10.2196/jmir.7747
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Introduction
People with agoraphobia have considerable impairment in their
daily lives as a result of persisting avoidance of places and
situations. Lifetime prevalence of agoraphobia with and without
panic disorder in the adult population has been reported to range
from 0.8% to 2.6% in American and European community
samples [1,2]. Agoraphobia has been ranked as one of the most
chronically persistent disorders [3], with higher rates of
work-related inactivity and disability than with other chronic
conditions [4,5].
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The standard psychological treatment for agoraphobia symptoms
is cognitive behavioral therapy (CBT), which is also
recommended by the UK National Institute of Health and Care
Excellence [6]. People with agoraphobia have catastrophic ideas
regarding the likelihood of threat in a situation or environment,
such as fainting and being ignored or ridiculed by others [7,8],
and as a consequence engage in “safety behaviors” to prevent
the expected catastrophe and reduce anxiety. Such safety
behaviors preserve and might even enhance the maladaptive
beliefs and thus maintain anxiety [9,10]. In CBT, cognitive
restructuring is used to challenge catastrophic cognitions and
unrealistic predictions, and to generate alternative, more realistic
expectations. Behavioral experiments may be conducted to help
disconfirm such beliefs and drop safety behaviors [8]. Moreover,
imaginal or in vivo exposure to the feared situations is used to
reduce situational avoidance and phobic anxiety. Breathing and
relaxation exercises are sometimes employed to help the patient
cope with overwhelming stress.
The effectiveness of CBT in the treatment of agoraphobia has
been demonstrated in several studies. A systematic review and
meta-analysis [11] examined the effectiveness of psychotherapy
and pharmacotherapy in the treatment of panic disorder, with
the majority of participants also having agoraphobia. They
identified 23 randomized controlled trials (RCTs) and showed
that, although combined psychotherapy and pharmacotherapy
produced the best results in the short term, in the long term
combined treatment was as effective as psychotherapy alone,
and both treatment groups were superior to pharmacotherapy
alone. Among the different types of psychotherapy, CBT had
the strongest evidence. More recent studies have also provided
support for CBT as an effective treatment in agoraphobia
patients [12-15] in line with earlier studies [16].
Even though CBT has been established as the preferred and
most effective treatment for agoraphobia and panic, many people
remain untreated. From the population of people with anxiety
disorders in developed countries, only 16.7% seek help from a
mental health professional, and only 21.3% of those receive
CBT [17]. Despite the fact that CBT has nowadays become
more widely available, certain barriers to treatment may explain
the low levels of self-seeking in people with agoraphobia. For
example, fear of stigmatization, lack of psychoeducation, long
waiting lists, transportation problems, and time constraints
significantly limit access to CBT [18-20]. In addition, the very
nature of agoraphobia, which may include fears of leaving the
house and using public transport, may make it even more
difficult for people to actively seek professional help. To
overcome such barriers, effective interventions that are easily
accessible and do not require therapist face-to-face contact
should be available.
Internet-based or computerized interventions can be considered
as acceptable alternatives to standard treatments, as they can be
clinically effective and minimize treatment barriers for users.
Such interventions can be self- or therapist guided, presenting
materials of cognitive behavioral principles and methods in a
series of lessons, which are typically accompanied by homework
tasks and supplementary information. Systematic reviews show
that computerized CBT (CCBT) is as beneficial as therapist-led
CBT in the treatment of anxiety disorders such as panic disorder,
and is more effective than treatment as usual or waiting list
conditions [21,22]. CCBT can also reduce therapist time [21]
and have good acceptability, as shown by adherence and
satisfaction levels [22]. A more recent review of Internet CBT,
including 8 trials of panic disorder with and without
agoraphobia, concluded that Internet CBT was as efficacious
as face-to-face CBT and more efficacious than waiting list,
attention, information, and online discussion control groups
[23].
One promising mode of delivering computerized interventions
are mobile phones, because of their relatively low cost and
widespread use [24]. Since users carry their mobile devices with
them in almost any situation, mobile phones, and particularly
smartphones, might facilitate engagement with exposure
exercises in the users’ natural environments. Although mobile
apps have been tested for several conditions, such as unipolar
depression [25], borderline personality disorder, and substance
abuse [26], to date there has been no study testing an app that
primarily targets agoraphobic symptoms. Because of the
isolative nature of agoraphobia and the extreme avoidance
behaviors, an app that could be easily downloaded over the
Internet onto patients’ phones or tablets, requiring no traveling
to sites, might be especially appealing and convenient for this
population.
This study was a Web-based RCT aiming to test the clinical
effectiveness of a novel mobile app for agoraphobia in a
community-based sample. The treatment app, Agoraphobia
Free, developed by Health eLiving Partnership Ltd (HeLP) for
the iOS and Android operating systems, provides an interactive
game-based intervention using cognitive behavioral techniques
that target agoraphobia and panic. The comparator was a
stress-reduction app (Stress Free), which does not address
agoraphobic symptoms or panic, but stress and anxiety in
general. Both interventions were self-guided and were evaluated
over a period of 12 weeks. Adults that self-identified with
agoraphobia were randomly allocated to the 2 treatment arms
and completed self-reported assessments at baseline, midpoint
(6 weeks), and end point (12 weeks) of the trial. The primary
objective was to examine whether an agoraphobia-specific
intervention would be more effective than a generic,
anxiety-related intervention. A secondary aim was also to assess
the level of engagement with these interventions and the
feasibility of conducting such a trial over the Web.
Methods
Design
The study was a Web-based, assessor-blinded, parallel-group
RCT with an active control group. Participants were individually
randomly allocated (ratio of 1:1) to either the treatment group
or the control group at baseline and were given an equal amount
of time to complete each intervention (12 weeks). Data were
gathered automatically through online collection of anonymized
data, without any researcher intervention. The primary outcome
was the degree of symptom severity, as measured by the
self-reported version of the Panic and Agoraphobia Scale [27]
at end point.
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Participants
Inclusion Criteria
Participants needed to be adults (aged ≥18 years) and identify
themselves as having agoraphobia. Participants also had to be
willing and able to provide informed consent to participate in
the trial.
We used no diagnostic check, as the aim was to recruit a
community sample that would reflect the nature of the
population that would use the apps in a real-world setting, where
no screening or check would be required.
Exclusion Criteria
The exclusion criteria were as follows: (1) inability to give
informed consent due to significant cognitive or intellectual
impairment, (2) no adequate understanding of English as a first
language, and (3) not having a mobile device than could run
the app as designed.
Recruitment and Setting
A website was set up for the trial on which advertisements and
all relevant information and updates were posted. The website
was hosted by HeLP Ltd (currently known as Thrive Therapeutic
Software). Advertisements of the trial were also posted on social
media (eg, Facebook, Twitter), support groups and forums,
websites of relevant organizations such as Anxiety UK, blogs,
and university websites. We also individually contacted
members of anxiety support groups via Facebook or forum
messages. We created a mailing list of people subscribing their
interest in the trial, whom we encouraged to stay in touch until
the trial commenced. Moreover, contacts of the Chief
Investigator that were working in health-related settings were
encouraged to inform any relevant clients or representatives
about the study. There were 2 rounds of recruitment in order to
achieve a larger number of participants.
We always contacted participants via email. Initially, those who
expressed interest in participating followed a link to the online
information sheet and consent form, which outlined the
eligibility criteria and information about the trial. Through
consenting to participate and answering a series of questions,
participants confirmed that they met the criteria and understood
the purpose of the study. Participants also provided their email
addresses and names, though the latter was optional. Participant
codes were then assigned to those who consented, and details
about their mobile devices (smartphones or tablets) and
demographics (age and sex) were obtained. Participants were
instructed to use only their participant code to identify
themselves.
Participants received invitations for the apps, which were
available to use for free. Emails also contained links to weekly
surveys on app use and links to questionnaires, a description of
the specific survey questionnaire, links to the calendar and the
main website of the trial, information about the upcoming
survey, and useful contact details. A Frequently Asked Questions
section was set up on the main website. Data were collected
online and could only be accessed by the researchers.
Interventions
Agoraphobia Free
The treatment app was Agoraphobia Free (version 0.8),
developed by Thrive Therapeutic Software for the treatment of
agoraphobia, and this was the first time that it was evaluated.
The app was a game-based interactive intervention, with
3-dimensional characters and situations that simulate real-life
environments. Specifically, the app presented a case example
of a virtual character who had agoraphobia. The user was
required to guide her, through the help of the virtual therapist,
to complete the different therapeutic tasks. Those tasks were
based on CBT principles, comprising psychoeducation,
reflection, cognitive restructuring, interoceptive exposure, and
systematic desensitization. The 3 overarching goals were to
decrease the virtual character’s catastrophic cognitions, safety
behaviors, and physiological arousal. In this way, users were
able to progress through the character’s recovery and treatment,
and build the formulation of her difficulties. At the same time,
users were asked to apply the techniques they used in the case
example to their own situation. Therefore, by using the
character’s recovery journey as a template, users learned how
to reduce their catastrophic thinking, their safety behaviors, and
physiological arousal.
At the beginning of the intervention, we asked participants to
set a hierarchy of goals they would like to achieve (eg, going
out of the house, going to the supermarket). At the end of each
session, they were required to complete each one of those goals
in order, using the techniques and strategies they had learned
in the intervention. The sessions were designed so that the tasks
became increasingly more challenging as participants progressed
through the intervention. The sessions needed to be completed
in the order they were presented in for the next ones to become
unlocked. There were 10 sessions in total, and the participants
were asked to complete 1 or 2 sessions per week at their own
pace, and reminders for those were sent weekly. Multimedia
Appendix 1 shows an outline of each session.
Stress Free
The control app was Stress Free (version 1.3) developed by
Thrive Therapeutic Software, which focused on teaching
relaxation techniques and generic CBT skills though a virtual
therapist. The app also included a few distraction techniques
presented in the form of games that required attention to help
individuals cope with acute anxiety. The intervention was
presented initially as a linear training program using video and
audio guides. The user first learned diaphragmatic breathing,
then differential deep muscle relaxation, then self-hypnosis, and
finally meditation. These relaxation techniques have been
previously shown to be effective in reducing stress [28,29].
Participants rated their anxiety before and after relaxation
sessions using a visual analog scale. After completing the
training, they were familiarized with CBT concepts such as
negative automatic thoughts and the process of challenging
them. Finally, we gave participants a daily goal to complete,
such as doing 3 sessions of diaphragmatic breathing or a
10-minute session of meditation. In between sessions,
participants were prompted to record their anxiety on a CBT
journal. The app only targeted stress and anxiety in general, so
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it was not specific to agoraphobia. In the original version, there
was no maximum limit of sessions that users could go through
until they mastered the techniques. However, for the purpose
of the trial, we asked participants to complete 10 sessions in
total, so as to match the number of sessions required from the
treatment group.
Table 1 compares the 2 apps by showing which components
and exercises were present in each. Although some components
were common to both apps, in Agoraphobia Free they were
specifically tailored to agoraphobia. In Stress Free the exercises
addressed stress and anxiety in general without referring to
agoraphobia. The 2 apps were matched for the number of
sessions required and time to complete the interventions
(minimum: 6 weeks, maximum: 12 weeks). No training,
supervision, or guidance was offered before or during the trial,
and only a basic description of each app was provided. Any
questions participants had regarding the app or any technical
issues they encountered were resolved through email. Weekly
reminders and short surveys were sent to promote engagement
and monitor progress, and the completion of 1 to 2 sessions per
week was recommended for both groups. We also informed
participants at the beginning of the trial that, when they
completed the intervention, they would receive a link to
download the app they did not receive for free, as a reward for
taking part and an additional incentive to complete their assigned
intervention. Participants were assured that they would not be
asked any questions about the second app, as it would not be
part of the research.
The 2 apps were available on Android and iOS. Multimedia
Appendix 2 shows screenshots of the apps.
Outcomes
The primary outcome was the severity of agoraphobic and panic
symptoms, measured by the PAS [27]. The questionnaire was
administered online in a self-report format at baseline, midpoint
(6 weeks), and end point (12 weeks) of the trial. Reminders
were emailed to those who did not reply to the questionnaires
before the prespecified deadline. Participants rated the symptoms
they experienced in the previous week on a 5-point scale. The
questionnaire comprises 14 items, although only 13 of those
are used to calculate severity scores. The items are grouped into
5 subscales: (1) Panic Attacks, assessing frequency, severity,
and duration of panic attacks, (2) Agoraphobic Avoidance,
assessing frequency of avoidance, and number and relevance
of avoided situations, (3) Anticipatory Anxiety, assessing
frequency and severity of anxiety, (4) Disability, assessing
impairment in family life, social relationships, and employment,
and (5) Worries about Health, assessing worries about damage
to health and assumption of organic disease. The scale was
originally validated in a sample of 235 panic patients and has
shown good internal consistency (Cronbach alpha=.88),
test-retest reliability, and good internal and external validity
[27,30]. Cronbach alphas for this study’s sample indicated good
internal consistency, with alpha=.84 for the overall scale.
Coefficients for individual subscales ranged from .41 to .88.
The scale has been shown to be sensitive to change due to
treatment in 2 clinical trials [31,32].
The secondary outcomes were completion of the intervention
and engagement with the apps. Completion of the interventions
was assessed in the short online surveys that were sent weekly,
by asking participants if they had used the app, how much time
they used it for over the past week, and how many sessions they
had completed. If participants claimed that they had not used
the app, they were asked to give reasons.
Sample Size
We estimated the sample size on the basis of using the self-rated
version of the PAS (SD 10.3) as the primary outcome measure.
At least 68 participants in each arm were needed to detect a
5-point between-group difference, with a 2-sided significance
level set at 5% and power at 80%. Given the high dropout rates
in Web-based trials [33], the aim was to recruit at least 150
participants in total.
Table 1. The different features present (indicated by “X”) in each app.
Agoraphobia Free appStress Free appApp features
XXRelaxation technique training
XXAutomated activity goals
XXCCBTa basic tutorial
XXCCBT journal with prompts
XXMaintenance sessions
XXSelf-soothing strategies
XXDistraction techniques
XStructured CCBT program
XGoal setting by user
XConstruction of exposure hierarchy
XDevelopment of a formulation
XRelapse prevention session
aCCBT: computerized cognitive behavioral therapy.
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Randomization
We used a random computer-generated sequence to randomly
allocate participants to the 2 intervention groups. The random
allocation sequence was retrieved from a website that generates
truly random numbers [34], by a person outside the research
team. We applied block randomization to ensure equal numbers
of participants in each group (ratio of 1:1). Participants were
automatically allocated to intervention groups by a formula on
Excel version 14.6.6 (Microsoft Corporation) using the random
number sequence, which was coordinated by another contact
who was not a member of the research team. The random
sequence and the allocation of participants to groups were
concealed from research staff throughout the trial. The same
person sent emails to participants containing the link to the
assigned app after they had returned the baseline questionnaire.
Blinding
The trial was assessor blinded, as researchers were blinded to
treatment allocation throughout the trial and during the statistical
analysis. This was achieved by having a person outside the
research team to manage treatment allocation and personal
communications with the participants. Any questions or
comments made in the surveys were forwarded from this contact
to research staff, excluding any participant details or codes. This
was to ensure that the researchers remained blinded to treatment
allocation, as some comments contained information about the
specific app the participants were using. Researchers did not
have any access to data regarding treatment allocation, as those
were stored on a secure database, separate and protected from
other research files. During data collection and analysis, only
numerical codes were used to indicate group allocation.
Researchers did not know which groups those referred to until
the end of the analysis.
Blinding the participants was not possible, as the apps were
clearly labelled as “Stress Free” and “Agoraphobia Free,” and
masking those would require significant changes in the software,
which were not feasible. Moreover, even if the apps were not
differentially labelled, it is very likely that participants would
have become aware of which treatment group they were assigned
to because of the intervention content and the extent to which
it addressed agoraphobia.
Ethics
The research was approved by the Roehampton University
Ethics Committee (reference number: PSYC 14/ 117). The trial
was registered and reported in accordance with the Consolidated
Standards of Reporting Trials (CONSORT)-EHEALTH
checklist (Multimedia Appendix 3) [35]. Data were kept
anonymized and protected according to the UK Data Protection
Act [36]. We could obtain information about adverse events or
effects of the interventions from feedback participants provided
in the weekly surveys.
Analysis
We analyzed the data on Stata version 14 (StataCorp LLC). We
checked baseline data for normality and obtained descriptive
statistics to capture the demographic and clinical characteristics
of the sample. The analysis performed was intention-to-treat,
as requested in the CONSORT [37]. All participants who
completed the baseline assessment were included in the analysis
as they were randomly allocated.
We used a linear mixed model to analyze the data, with a
random effect of participant, and fixed effects of time (baseline,
midpoint, end point), group (Agoraphobia Free and Stress Free),
and the interaction between time and group. The estimated
baseline PAS score was constrained to be identical in the 2
groups, thus adjusting for baseline and allowing the relationship
between baseline and follow-up scores to differ at each time
point. Another advantage of this statistical method is that the
data from all participants contribute to the analysis, even if there
is a substantial amount of missing data at follow-up [38]. We
used an unstructured residual covariance matrix to allow for
correlations within participants between the different time points.
Statistical significance was taken at the 5% level (P<.05).
We conducted a planned secondary completers’ analysis using
the same data analytic strategy as the intention-to-treat analysis.
This analysis included only those participants who were
identified as intervention completers.
Results
Participant Flow
The first phase of recruitment started from September 2014 and
ended in late February 2015, and the second phase started in
March 2015 and concluded in April, 2015. In the first round,
153 participants consented to participate, and we recruited 17
additional participants in the second round. The procedure
following recruitment was the same in both samples. Data
collection ended in June 2015. Figure 1 shows how the total
sample of 170 participants progressed through the trial.
After 171 individuals consented to participate, 1 wanted to
withdraw from the trial. The rest were randomly allocated into
the 2 arms, but were not told which app they were assigned to
at that point. Although the aim was to assign equal numbers of
participants to each group, at each stage of randomization, the
treatment group happened to have 1 more person than the other
group, because the number of participants recruited each time
was odd, and researchers were blinded to the allocation
sequence.
We asked participants to fill in a form with their demographic
and device details to register for the intervention so that we
could set up the corresponding app invitations. A total of 18
participants did not return the form and did not reply to emails,
even after they had been sent several reminders; thus, we treated
them as dropouts and excluded them from the trial. The baseline
PAS questionnaire was then sent and had to be completed in
order for participants to proceed and receive the intervention.
A total of 10 individuals did not return the questionnaire and
did not reply to any emails. Up to this point, participants were
still unaware of the group they were assigned to; thus, their
exclusion from the trial was very unlikely to introduce any bias.
The remaining 142 who completed the PAS were sent their
allocated intervention, but 6 participants could not download
the app on their device, despite efforts to resolve the technical
issues.
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Figure 1. Flow of participants through the different stages of the trial.
After baseline, 39 participants did not want to continue with the
trial and dropped out, while 29 participants did not reply to
emails and did not complete the questionnaires. We included
all participants who provided baseline data in the analysis.
Baseline Characteristics
Of the 142 participants who completed the baseline assessment,
2 did not give details of their age and sex (1 from each treatment
arm). Of the remaining 140, 118 (84.3%) were female and had
a mean age of 39.7 years (SD 11.3). Overall, the mean
participant PAS total score was 30.3 (SD 8.7), and the scores
were normally distributed (Shapiro-Wilk test: W=.985, P=.14).
The mean PAS total score fells into the severe range and was
much higher than that of the original sample used in the
validation of the scale [27], which reported a mean score of
23.5, SD 10.3. Our sample also had a higher proportion of
women than the original sample (of whom only 57% were
women) and a slightly higher age (mean 36.09 years in the
original sample). A significant proportion of our sample
(114/142, 80.3%) had severe or extremely severe Agoraphobic
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Avoidance, while 85.2% (121/142) avoided more than 8
situations. None of the participants scored 0 on the Agoraphobic
Avoidance subscale, which indicates that all of them experienced
agoraphobic symptoms to some degree. The lowest score on
that scale was 1.67, indicating mild Agoraphobic Avoidance.
In contrast, 29 participants (20.4%) obtained a score of 0 on the
Panic Attacks subscale, which suggests that some participants
experienced agoraphobia in the absence of panic attacks.
Overall, agoraphobic symptoms were more prominent than
panic symptoms in this sample.
Table 2 shows the demographic and clinical baseline
characteristics of the participants by group. The 2 groups did
not differ statistically on any of those characteristics at baseline
(all P>.05).
Missing Data
A total of 68 (47.9%) participants had missing outcomes.
Overall, the differences between participants with missing data
and those without were not statistically significant on any of
the baseline variables examined. There were no significant
differences in age (t138=0.85, P=.40) sex (χ
2
1=0.6, P=.45), or
clinical symptom severity (t140=1.32, P=.19). There were 37
participants (54%) with missing data in the Agoraphobia Free
arm and 31 (46%) in the Stress Free arm. The relationship
between missing data and treatment arm was not significant
(χ21=0.5, P=.49). Therefore, participant attrition did not seem
to be biased with regard to group or any other baseline factor.
Main Analysis
We produced a linear mixed model assessing the relative effects
of each intervention on PAS scores at the 2 follow-up time
points. Table 3 presents the estimated differences in PAS scores
for the Agoraphobia Free group compared with the Stress Free
group adjusted for baseline score at the 2 time points.
At end point, symptom severity scores decreased in both groups,
but there was no evidence that the changes were significantly
greater among participants of the Agoraphobia Free group than
among those in the Stress Free group. Similarly, at midpoint
there were no significant differences in symptom severity
changes between the 2 groups. Therefore, there were no
significant differences between the 2 groups. Figure 2 presents
the differences on the primary outcome for each group over
time.
We carried out the same linear mixed model analysis (n=142)
using each PAS subscale as the dependent variable to examine
whether there was a difference between the 2 groups in terms
of symptom dimensions. We found no significant interactions
between group and time for any of those outcomes (all P>.05).
We conducted within-group contrasts to examine the degree of
change in symptom severity over time. For both Agoraphobia
Free (n=73) and Stress Free (n=69), there were statistically
significant improvements in symptom severity from baseline
to midpoint and end point. Table 4 presents the results.
Table 2. Baseline demographic and clinical characteristics of each treatment arm.
Range of PAS scoresStress Free app (n=69)Range of PASa scoresAgoraphobia Free app (n=73)Characteristics
N/A40.23 (12.21)N/Ab39.21 (10.45)Age (years), mean (SD)
N/A54 (79.4)N/A64 (88.9)Sex (female), n (%)
PAS scores, mean (SD)
6-4729.80 (8.72)9-5030.77 (8.72)Total
0-3.331.52 (0.88)0-41.58 (1.05)Panic Attacks
2-43.24 (0.52)1.67-43.30 (0.57)Agoraphobic Avoidance
0-42.59 (1.01)0-42.70 (0.94)Anticipatory Anxiety
0-42.47 (1.09)0-42.39 (1.16)Disability
0-41.46 (1.11)0-41.78 (1.17)Worries about Health
aPAS: Panic and Agoraphobia Scale.
bN/A: not applicable.
Table 3. Intention-to-treat analysis at end point (12 weeks) and midpoint (6 weeks), n=142 .
Effect estimateStress Free mean (SD)Agoraphobia Free mean (SD)Time point of PASa score
P value95% CIDifference
.64–1.96 to 3.200.3823.95 (16.51)24.33 (16.81)End point (primary outcome)
.83–3.13 to 3.890.6227.03 (13.27)27.66 (13.37)Midpoint
aPAS: Panic and Agoraphobia Scale.
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Figure 2. Clinical symptom severity as indicated by the total score on the Panic and Agoraphobia Scale (PAS) in each group at trial baseline, midpoint,
and end point.
Table 4. Within-group contrasts capturing the differences in Panic and Agoraphobia Scale total score between time points within each treatment arm
(n=142).
Baseline-end point contrastBaseline-midpoint contrastTreatment arms
P value95% CIDifferenceP value95% CIDifference
<.001–8.49 to –3.44–5.97.005–4.48 to –0.79–2.64AFa
<.001–8.82 to –3.87–6.35<.001–5.09 to –1.43–3.25SFb
aAF: Agoraphobia Free app.
bSF: Stress Free app.
Completers’ Analysis
Data on completion were available from participants who
consistently replied to the surveys and questionnaires (n=74).
There were 56 participants who completed 80% or more of the
assigned intervention; 25 of those received Agoraphobia Free
and 31 received Stress Free. Of those who were deemed
noncompleters, 11 were in the Agoraphobia Free arm and 7 in
the Stress Free arm. There was no relationship between treatment
arm and completion of intervention (χ21=1.5, P=.22).
We examined differences in completers’ symptom severity
between the 2 intervention groups. We produced a linear mixed
model, with random effect of participant, and fixed effects of
time (baseline, midpoint, end point), group (Agoraphobia Free
and Stress Free), and the interaction between time and group.
In line with the intention-to-treat analysis, there were no
significant differences between the 2 groups at end point or
midpoint, as Table 5 shows. The within-group changes at each
follow-up time point compared with baseline were significant
in both groups (all P<.001). Therefore, there were significant
reductions in symptom severity in both groups over time, but
those reductions were equivalent across the 2 groups.
Clinical Significance
Wichmann et al [39] recently showed that an overall
postintervention (ie, face-to-face CBT) decrease in the total
PAS score of about 4 to 5 points represents a clear clinical
change in terms of quality of life and functioning. This is slightly
smaller than the change we observed in our study (6 points) for
end point PAS scores compared with baseline. The decrease in
symptom severity was even more marked in the completers’
sample (7 points in the Stress Free group and 10 points in the
Agoraphobia Free group). Therefore, it seems that both apps
were overall successful in achieving clinically significant
change.
Of the 74 participants who provided data at end point, 46 (62%)
had a reduction of 5 or more points on the PAS at end point. A
total of 25 (66%) participants in the Stress Free group and 21
(58%) participants in the Agoraphobia Free group improved at
least 5 points on the PAS at end point.
Safety and Use of Apps
A total of 7 participants (Agoraphobia Free: n=3, Stress Free:
n=4) commented that certain app components were mildly
stressful (eg, the distraction games, background music). There
were no reported adverse events experienced as a result of either
intervention. Also, 7 participants commented that the
Agoraphobia Free app was confusing to follow at certain points.
Another participant explained that they could not use the
treatment app as much as they wanted to because they had
depression and did not feel motivated.
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Table 5. Completers’ analysis at end point (12 weeks) and midpoint (6 weeks), n=56.
Effect estimateStress Free mean (SD)Agoraphobia Free mean (SD)Time point of PASa score
P value95% CIDifference
.30–6.21 to 1.91–2.1523.73 (12.12)21.58 (13.10)End point
.61–4.05 to 2.37–0.8426.93 (10.40)26.09 (11.15)Midpoint
aPAS: Panic and Agoraphobia Scale. The mean baseline PAS score for both groups was 31.23.
Discussion
Principal Findings
The results from this RCT showed that participants who received
Agoraphobia Free did not improve more than those who received
the Stress Free app. Both groups showed reductions in symptom
severity over time that were statistically significant, but those
reductions seemed to be equivalent across the 2 groups. Both
treatment apps were safe to use and yielded similar completion
rates. Moreover, completers of either intervention showed
marked improvements in symptom severity, with a 10-point
drop in the PAS at end point compared with baseline in the
Agoraphobia Free group. However, findings from this analysis
should be considered with caution, as we performed the analysis
on a specific subgroup of participants, and there is the possibility
that factors other than the intervention influenced the outcome
(eg, participant expectations). In addition, the power of this
analysis was very low (below 50%) due to the small sample
size.
Throughout the trial, participant attrition was particularly high,
as almost half of the participants recruited dropped out of the
trial or stopped responding to emails. Dropout rates were similar
to those reported in other Web-based trials of self-guided
interventions [40,41]. Many participants dropped out after
providing consent, which we had not expected. We had to
exclude those participants from the analysis, as no baseline data
were available. It is unlikely that this exclusion of participants
could have led to bias, as participants at that point were unaware
of the groups they were randomly allocated to, and thus attrition
was random between the 2 groups. Similarly, participants who
dropped out or stopped responding after receiving the
intervention did not seem to differ from those who engaged in
the trial, and attrition was equivalent across the 2 groups. The
analytic strategy we chose is robust and uses all available data
from each participant, producing less-biased results than other
methods of analysis and data imputation [38]. Overall, the fact
that participant attrition appeared random, in addition to the fact
that we used data from all participants in the analysis, offer
support and confidence in the validity of the study findings.
Limitations
The trial had a few limitations. There was no follow-up after
the completion of the intervention. Therefore, it was not possible
to investigate whether the improvements in symptom severity
were maintained over time or whether there were any differences
between the 2 groups after a few months of using the apps. The
information collected regarding the characteristics of the sample
was also limited, as there were no data on comorbid disorders,
other psychological or physiological treatments, or other
demographic characteristics such as ethnicity and computer
literacy. This information might have provided better insights
into the sample and could have been related to intervention
efficacy. There was also limited information on app completion,
as the information available relied on participant report and we
were not permitted to extract app use data for participants
individually. Moreover, participants could not be blinded, which
is a common limitation in eHealth trials.
Another limitation of the study was the absence of a waitlist
control group. The comparison of 2 active groups that shared
very similar features tested the effects of agoraphobia-specific
therapeutic elements over and above those of a generic
anxiety-related treatment. There was no control, however, for
the effect of time, and it is therefore not possible to conclude
whether the improvements observed were not because of natural
recovery processes or factors other than the intervention.
Although a waitlist control group would be a necessary addition
in a future trial in order to clearly establish treatment efficacy,
the primary focus of this study was to demonstrate whether a
disorder-specific mobile-based intervention is warranted in the
treatment of agoraphobic symptoms, compared with a more
generic approach addressing anxiety.
Despite its limitations, the study also presented certain strengths.
First, it is, to our knowledge, the first RCT to directly compare
an agoraphobia-specific app with a generic anxiety-related app.
Second, the sample recruited online was characterized by severe
clinical symptoms and especially high levels of agoraphobia,
which shows that recruitment based on self-identification is
feasible and reliable. Such a sample may have also been hard
to reach in a traditional multicenter trial with assessors
conducting screening interviews, which would have been time
consuming and would require a lot of resources. The trial was
minimally intrusive for the participants, as it requested a limited
amount of information, and the tools used were short and easy
to complete. This helped achieve fair recruitment and response
rates without any explicit individual guidance. Third, an
important strength of the study was its external validity. The
apps were offered as they would be offered in real-world
settings, without requiring any screening of users or close
supervision. There were very few restrictions on who could
participate, therefore making our findings more easily
generalizable to an Internet population who would simply
download the app if they thought it would be relevant to them.
Fourth, the results of the study provide an insight into what we
would realistically expect from an unguided mobile intervention,
such as a substantial dropout rate, small symptom change, and
highest efficacy for those who consistently engage with and
complete the intervention.
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Comparison With Prior Work
The findings of this study relate to previous studies on the
treatment of anxiety disorders. The findings add to the evidence
base of computerized cognitive behavioral interventions
examined in anxiety disorders [21-23]. Our findings are also
consistent with previous studies showing that completers of
Web-based interventions for panic (with or without agoraphobia)
benefit the most [40,42]. Importantly, the lack of a significant
difference between the 2 groups indicates that a generic
anxiety-related app and a diagnosis-specific app are equally
effective in treating agoraphobic symptoms. This finding is in
line with evidence supporting the efficacy of transdiagnostic
(ie, unified, nonspecific) cognitive behavioral treatments in
anxiety disorders. Transdiagnostic treatments are based on the
premise that “commonalities across disorders outweigh the
differences” [43]. A recent systematic review and meta-analysis
showed that transdiagnostic treatments can be as efficacious as
diagnosis-specific treatments in reducing anxiety symptoms
and more effective than waitlist or attention control conditions
[44]. Transdiagnostic CBT programs tested in different anxiety
disorders (including panic disorder) can also be successfully
administered via the Internet [45], producing effects equivalent
to those of disorder-specific Internet-based interventions [46,47].
Moreover, transdiagnostic CBT does not differ from
diagnosis-specific CBT in terms of treatment credibility [48].
Our study adds to this body of evidence suggesting that, for
people with agoraphobia, an agoraphobia-specific app does not
produce any additional benefits in relation to a transdiagnostic
anxiety-targeting app.
Clinical Implications
The findings of this study have implications for clinical practice.
This trial shows that mobile apps can be successfully
administered to a particular population that is hard to reach
otherwise, without requiring guidance by a clinician. This could
potentially save time for clinicians, while it could also be more
convenient for patients and help them overcome many barriers
to treatment, such as traveling to sites or long waiting lists.
Furthermore, a self-guided app could be easily introduced into
a stepped care model as a minimal intervention, as it is less
intense than a clinician-guided intervention or individual therapy
[49]. Since there was no evidence of superiority of one type of
intervention over the other in this study, a choice between a
generic and a targeted approach could be ultimately based on
clinical judgment or patient preference. However, as suggested
by Norton and Barrera [48], a generic anxiety-targeting app
might be more resource efficient and easier to implement and
disseminate than a diagnosis-specific app.
Conclusions
Overall, this RCT suggests that transdiagnostic anxiety-targeting
mobile apps can be as effective as disorder-specific apps for
people with agoraphobic symptoms. Results show that
individuals who identify as having agoraphobia do not benefit
more from an agoraphobia-specific than from a transdiagnostic
app. Future research conducted by independent research teams
should replicate the results of this study, further investigating
the possibility that mobile-based transdiagnostic interventions
for anxiety can be as effective as current gold standard
disorder-specific interventions. A trial with a larger sample size
and a waitlist control group is warranted to establish intervention
efficacy and cost effectiveness in this population. Additionally,
the collection of more-extensive demographic and clinical
information can help examine under which circumstances a
diagnosis-specific or a generic approach is more appropriate.
For example, future research could investigate whether patients
with more severe symptoms or with comorbid disorders (eg,
depression) benefit more from one type of intervention than the
other. While there is still much to learn about treatment
approaches in anxiety disorders, many studies, including this
one, show that e-mental health interventions can overcome
barriers and be effective in reducing clinical symptoms.
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